Pharma News and Headlines
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Pharma Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Tuesday recap

NewsDealsSocialBlogsVideosPodcasts
HomeIndustryPharmaNewsFDA Clears New Formulation of Lantheus' PSMA Imaging Agent
FDA Clears New Formulation of Lantheus' PSMA Imaging Agent
HealthTechBioTechPharmaHealthcare

FDA Clears New Formulation of Lantheus' PSMA Imaging Agent

•March 10, 2026
0
Radiology Business
Radiology Business•Mar 10, 2026

Why It Matters

The reformulation boosts manufacturing efficiency and supply‑chain reliability, expanding patient access to critical prostate‑cancer imaging and strengthening Lantheus’ market position.

Key Takeaways

  • •FDA clears Pylarify TruVu formulation
  • •Improved stability at higher radioactive concentrations
  • •Larger batch sizes enable broader distribution
  • •Commercial launch slated for Q4 2026
  • •Rolling geographic rollout minimizes workflow disruption

Pulse Analysis

Prostate‑specific membrane antigen (PSMA) PET tracers have become a cornerstone for staging and monitoring prostate cancer, offering higher sensitivity than conventional imaging. Lantheus’ original Pylarify (piflufolastat F‑18) received FDA approval in 2020 and quickly gained market share. The agency’s recent clearance of the Pylarify TruVu formulation marks the first regulatory endorsement of a reformulated PSMA agent, confirming that the new product meets safety and efficacy standards for detecting PSMA‑positive lesions in men undergoing definitive therapy or experiencing biochemical recurrence. Guidelines from NCCN and EAU now list PSMA PET as preferred imaging for high‑risk disease.

The TruVu version is engineered for greater radiochemical stability, allowing it to tolerate higher activity concentrations without degradation. This technical tweak translates into larger production batches, which high‑energy cyclotron facilities can synthesize and ship to a wider network of imaging centers. By reducing the need for frequent re‑fill runs, the reformulation improves manufacturing efficiency, cuts per‑dose costs, and strengthens supply‑chain resilience—critical factors as demand for PSMA PET scans accelerates across oncology practices. Lower batch frequency also reduces radioactive waste, aligning with sustainability goals in nuclear medicine.

From a commercial perspective, the timing aligns with a surge in prostate‑cancer diagnostics and the entry of competing F‑18 PSMA agents from European manufacturers. Lantheus’ ability to offer a more robust formulation could solidify its leadership, especially as insurers increasingly reimburse PSMA PET for staging and recurrence monitoring. The planned Q4 2026 rollout, delivered on a rolling geographic basis, aims to minimize workflow interruptions while expanding patient access, potentially driving broader adoption of precision imaging in urologic oncology. Lantheus is already negotiating with major cyclotron manufacturers to co‑optimize production protocols, further shortening lead times.

FDA clears new formulation of Lantheus' PSMA imaging agent

Read Original Article
0

Comments

Want to join the conversation?

Loading comments...